ATNM ATNM
Company Profile ↓Company Overview
ATNM (ATNM) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +11.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 11.11% |
Stock Price Performance
| 1 Year: | -54.90% |
| 6 Months: | -37.61% |
| 3 Months: | -40.58% |
| 1 Month: | -28.70% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)24.95 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 58.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 25 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 622.00K | 266.00K | 233.00K | 940.00K | 45.00K | 45.00K | - | - | - | - | - | - | - | - | 90.00K | - |
| Operating Income | -2.02M | -1.48M | -1.61M | -4.14M | -4.42M | -7.04M | -7.87M | -7.40M | -4.64M | -6.00M | -6.92M | -7.10M | -7.81M | -7.20M | -6.70M | -6.35M | -4.91M | -6.20M | -5.70M | -5.09M | -6.65M | -5.68M | -4.66M | -5.61M | -5.37M | -5.08M | -6.47M | -5.16M | -7.85M | -9.80M | -11.58M | -15.64M | -14.35M | -9.60M | -12.42M | -12.60M | -16.64M | -7.50M | -5.69M | -5.90M |
| Net Income | -689.03K | -2.78M | -1.42M | -16.70M | 3.52M | -6.08M | -3.07M | -7.46M | -3.95M | -4.40M | -6.62M | -6.60M | -8.06M | -7.05M | -6.32M | -6.32M | -4.86M | -6.15M | -5.67M | -5.03M | -6.60M | -5.67M | -4.62M | -5.54M | -5.32M | -5.02M | -6.42M | -5.13M | -7.77M | -9.47M | -11.04M | -15.18M | -13.28M | -8.67M | -11.35M | -11.57M | -15.94M | -6.88M | -5.13M | -5.52M |
| Diluted EPS | - | -0.13 | - | - | 0.10 | - | - | -0.20 | -0.10 | - | -0.15 | -0.14 | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.25 | -0.30 | -0.23 | -0.33 | -0.38 | -0.43 | -0.58 | -0.49 | -0.31 | -0.38 | -0.37 | -0.51 | -0.22 | -0.16 | -0.18 |
| R&D Expense | 1.09M | 509.26K | 778.23K | 1.59M | 2.13M | 4.14M | 4.05M | 3.84M | 2.83M | 3.77M | 4.15M | 5.69M | 4.57M | 4.45M | 5.03M | 4.47M | 3.33M | 4.23M | 4.34M | 4.01M | 4.83M | 4.15M | 3.51M | 3.79M | 4.28M | 3.63M | 4.71M | 4.37M | 4.66M | 6.77M | 7.85M | 11.08M | 11.62M | 6.63M | 8.82M | 9.77M | 7.70M | 4.88M | 4.25M | 4.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - | - | - | - | - | - | - | 1.14M | 1.03M | 81.00K | - | 90.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | - | - | - | -26.05K | -3.28M | -7.95M | -6.59M | -22.48M | -24.83M | -26.85M | -26.91M | -23.83M | -22.07M | -22.39M | -24.96M | -34.10M | -51.92M | -42.12M | -36.25M |
| Net Income | -5.09M | -3.19M | -3.53M | -5.73M | -4.58M | -6.05M | -5.62M | -5.57M | -3.43M | -467.27K | -3.44M | -8.36M | -10.77M | -24.69M | -21.03M | -24.32M | -26.60M | -23.65M | -21.90M | -22.21M | -24.77M | -33.02M | -48.82M | -38.24M | -33.89M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.20 | -1.37 | -1.83 | -1.27 | -1.09 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | 323.79K | 3.44M | 3.11M | 12.27M | 13.50M | 17.83M | 17.72M | 17.09M | 16.55M | 16.09M | 18.03M | 23.14M | 38.67M | 30.05M | 21.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | 150 | 6.20M | 5.79M | 5.77M | 7.57M | 26.59M | 22.53M | 18.34M | 14.89M | 11.67M | 66.40M | 80.39M | 114.19M | 81.44M | 76.90M | 51.77M |
| Total Equity | 1.11M | -1.73M | -1.68M | 1.57M | 439.12K | 74.28K | 1.82M | 3.46M | 4.16M | 845.16K | 399.06K | 992.01K | 1.15M | -1.56M | -1.92M | 21.97M | 18.01M | 13.67M | 8.81M | 5.64M | 61.32M | 73.55M | 66.48M | 36.38M | 32.76M | 7.83M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | 2.12K | 196.13K | 5.70M | 5.62M | 5.53M | 6.71M | 25.64M | 20.52M | 17.40M | 13.67M | 9.25M | 63.56M | 77.83M | 108.91M | 76.68M | 72.90M | 48.00M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | 94.77K | 84.48K | 4.64M | 7.33M | 9.49M | 4.61M | 4.52M | 4.67M | 6.08M | 6.03M | 5.08M | 6.84M | 47.71M | 45.07M | 44.14M | 43.94M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | 36.06K | 5.21M | 4.64M | 7.33M | 9.49M | 4.61M | 4.52M | 4.67M | 6.06M | 5.34M | 4.77M | 6.84M | 10.63M | 8.49M | 8.15M | 7.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.83K | -517.59K | -5.21M | -6.29M | -14.35M | -18.54M | -20.79M | -21.55M | -20.57M | -21.46M | -21.62M | -20.87M | 8.64M | -47.34M | -33.07M | -24.58M |
| Investing Cash Flow | 0 | 0 | -2.36K | -16.59K | -186.42K | -47.79K | -109.82K | -24.74K | -96.09K | -64.00K | -253.00K | -133.00K | -366.00K | -153.00K | -11.00K | -104.00K |
| Financing Cash Flow | -9.81K | 6.03M | 5.13M | 6.22M | 15.71M | 37.53M | 15.78M | 18.81M | 16.98M | 17.11M | 76.18M | 35.22M | 23.11M | 14.87M | 29.32M | -217.00K |
| Capital Expenditure | - | - | -2.36K | -16.59K | -151.69K | -47.79K | -59.96K | -24.74K | -96.09K | -64.00K | -253.00K | -133.00K | -366.00K | -153.00K | -11.00K | -104.00K |
| Free Cash Flow | - | - | -5.22M | -6.31M | -14.50M | -18.59M | -20.85M | -21.58M | -20.67M | -21.53M | -21.87M | -21.00M | 8.28M | -47.49M | -33.08M | -24.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2,182.2% | -3,311.1% | -64,098.8% | - | -40,274.4% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2,165.6% | -3,205.5% | -60,269.1% | - | -37,652.2% |
| ROE % | 293.8% | 190.6% | -224.4% | -1,306.0% | -6,166.6% | -331.9% | -162.4% | -134.0% | -405.4% | -117.1% | -347.3% | -729.8% | 690.8% | 1,284.1% | -95.7% | -135.1% | -194.6% | -268.4% | -388.0% | -36.2% | -33.7% | -49.7% | -134.2% | -116.7% | -432.6% |
| ROCE % | - | - | - | - | - | - | - | - | - | 72.5% | -331.0% | -693.7% | 422.7% | 1,169.3% | -113.0% | -149.1% | -196.8% | -270.0% | -348.9% | -36.3% | -33.9% | -32.9% | -71.2% | -61.3% | -82.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATNM
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiswJBVV95cUxPakd6Wml2ampBRVdPYjBBV25sajFleExBSkptaHA1QUgxUGFUcnVjcnVJR0lramtsc3lqbDd0Q3YyeFFVNXVZYVA2THFDVXRpdUczZ0VfMTJPTDIyY2tFWUVBQm5hZEs0VlljVFZPWEZmSVgtZm0zelZRanU0dUFSM09aa3poQ25VMWhRQ2…
ATNM Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1kNjljWFRLcXRGLUI0ZFZkS3dzcG9IVExBTE9FTTNsX0VwdVFiYXVabmRqdnlHOGFWeENFZExaOFN1MXZ2RHFtSzR1TGpaQm4zNVdnOUJOaklXVTVEVlE?oc=5" target="_blank">ATNM Should I Buy</a> <font c…
ATNM Stock Price and Chart — AMEX:ATNM - TradingView
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE1lLW5XMmVBVjRpNDBHZU1hWjRid1Y2S01QUFRIazdzekZ0S01obW9XWXlOaGN0Y0x5QkNkQmFtVFZsUnpMRkh6bEM3cnp1OVh3T1dQeU04amk3dw?oc=5" target="_blank">ATNM Stock Price and Chart — AMEX:ATNM</a>&nb…
SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQSzF0LXF1azRaT2R6Q2w2dHg0Tkg2UXJMUGRoZE5TUWJSdUJvaUJkR0NLWDlWaXROUThwY05rdXZjZGhaQ2tGYmp0Q3pYdzFrMkJyNURNZTJvQWlTa1g2N291cTZSa2ZmR1JtMjA3RXhMYnU2SWtsbHN4S184UzZXTHNDZjh2RngwQjcyUG…
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - TMX Newsfile
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxON1dudkhCY0VWajFxVzZGSlRPeWxEVXdJdTR3X1NETHo0aG5LcVVlX0FUNUxhaUp1bzU1NlNsUGc1YlRDOHNYanpRM0N5dTB1S2JqeWFqVTRUT195S3ZEWFc4VHVRNFgyc095WjFuWGFrTGxWWHRfZDVLRkp2cS1mRWFMTFh5VEQ1ZVp3Rz…
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiswJBVV95cUxPWTZFa21UQXZKdFRKenBmQmZDdWNEYTFOOS1Dbk1rWlNlSEFsYkZ6NGo2bGt0clI5R2toeHBxOWdMaGdCWW9zZF8yZHFiTWRabVlGVDdSNmRIMk9zcDFKMTNKQl9PbGlDc3RXV0VNeW9ObUtpYjk1YWtjWjFKaHI4RERTZy16TWw2RXNNb1…
ATNM — Frequently Asked Questions
What is the current share price of ATNM?
As of 2026-08-05 17:25 PDT, ATNM trades at $0.75 on NASDAQ/NYSE. Its 52-week range is $0.75 to $1.79.
What is the P/E ratio of ATNM?
ATNM trades at a trailing price-to-earnings (P/E) ratio of -0.69.
Is ATNM a good stock to buy?
This page provides a data-driven analysis of ATNM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.